 |
Prospector
Profile
123-003
|
| |
| Synthetic Blood International, Inc. |
NAICS |
541710 |
| 3189 Airway Avenue, Building C,
Costa Mesa, CA 92626 |
Description |
Biotechnology |
| (714) 427-6363 |
Employees |
6 |
| http://www.sybd.com/ |
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-3.3300 |
| |
Assets |
(mil) |
1.8220 |
| |
Liability |
(mil) |
1.8450 |
| |
(for the year ended 2007-04-30) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Synthetic Blood International, Inc., reported a net loss of $931,939 for the three months ended October 31, 2007, which is higher than the $695,315 net loss incurred during three months ended October 31, 2006. For the six months ended October 31, 2007, the Company had a $1,959,166 net loss, slightly higher than the $1,406,385 net loss reported during the same period in 2006. At October 31, 2007, the Company's balance sheet showed an accumulated deficit of $32,979,349, stockholders' deficit of $1,697,989 and working capital deficit of $1,948,855.
|
| |
|
Intellectual Property:
The Company holds four U.S. patents (5,674,913; 5,824,703; 5,840,767; 6,167,887), three Australian patents (690,277; 722,417; 759,557), two Canadian Patents (2,239,170; 2,311,122) and one European patent (EPO 8697678B1) pertaining to the use and application of perfluorocarbons as gas transport agents in blood substitutes and liquid ventilation. Additionally, through an exclusive supply agreement with its perfluorocarbon supplier, the Company benefits from eight perfluorocarbon manufacturing process patents that further protect the perfluorocarbons contained in its products. The Company also has three U.S. patents (5,914,026; 5,964,993 6,343,225) and two Australian patents (720,712; 734,003) that protect important design features of the Company's implanted glucose biosensor. The Company holds exclusive licenses to three fundamental biosensor patents that represent the core technology used on its product. [SEC Filing 10-KSB 08-14-07]
|
| |
|
Description:
Synthetic Blood International engages in developing biotechnology products. It focuses in the development of Oxycyte, a product alternative to transfused blood for use in surgical and similar medical situations.
|
| |
|
Officers:
Chris J. Stern (Chair); Robert J. Larsen (Interim Pres., CE O, & CFO); Richard Kiral (VP- Research & Development)
|
| |
|
Auditor:
Haskell & White LLP
|
| |
|
Securities:
Common Stock-Symbol SYBD.OB; OTC BB; 140,859,926 common shares outstanding as of December 10, 2007.
|
| |
| |
| |
| return to main page |
|
|
